BPMX - BioPharmX Corporation

NYSE American - NYSE American Delayed Price. Currency in USD
0.8438
+0.0014 (+0.17%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Trade prices are not sourced from all markets
Previous Close0.8424
Open0.8400
Bid0.0000 x 1100
Ask0.0000 x 1100
Day's Range0.8110 - 0.8797
52 Week Range0.8110 - 7.3500
Volume268,345
Avg. Volume606,878
Market Cap8.843M
Beta (3Y Monthly)-0.09
PE Ratio (TTM)N/A
EPS (TTM)-2.2330
Earnings DateApr 24, 2019 - Apr 29, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.63
  • PR Newswire3 days ago

    BioPharmX Announces Last Patient Visit in Phase 2b Trial of BPX-04 for Papulopustular Rosacea

    SAN JOSE, Calif., May 22, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, announced today that the last patient in the Company's Phase 2b clinical trial of BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea, has completed their last clinical visit. "We are pleased to announce this important milestone and look forward to reporting topline results from the study in early July 2019, subject to successful database lock and results validation," said Dr. David S. Tierney, BioPharmX Chief Executive Officer. The randomized, double-blind, vehicle-controlled study enrolled 206 subjects with moderate-to-severe papulopustular rosacea.

  • PR Newswire29 days ago

    BioPharmX Completes 1-for-25 Reverse Stock Split

    SAN JOSE, Calif., April 26, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announces the completion of the reverse stock split previously announced on April 15, 2019 to regain compliance with certain NYSE American continued listing standards related to the low price per share of the Company's common stock. The reverse stock split became effective at 4:01 pm Eastern Time on April 25, 2019.

  • PR Newswirelast month

    BioPharmX Announces Reverse Stock Split

    SAN JOSE, Calif., April 15, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that its Board of Directors has approved a reverse stock split of its common stock at a ratio of 1-for-25. The reverse stock split will become effective on April 25, 2019 (the "Effective Date"), and the shares will begin trading on the split-adjusted basis on the NYSE American under the Company's existing trading symbol "BPMX" at market open on April 26, 2019. The new CUSIP number following the reverse stock split will be 09072X 309.

  • PR Newswire2 months ago

    BioPharmX Announces $3.9 Million Offering

    SAN JOSE, Calif., March 21, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has entered into securities purchase agreements with certain institutional investors for the purchase and sale of 43,645,000 shares of common stock at a price of $0.09 per share in a registered direct offering. Net proceeds of the offering will be used to advance the BioPharmX clinical programs, product development and general corporate purposes. The shares of common stock were offered by BioPharmX pursuant to a shelf registration statement on Form S-3 (File No. 333-229459) which was declared effective by the Securities and Exchange Commission (SEC) on February 13, 2019.

  • ACCESSWIRE2 months ago

    Watch These Four Healthcare Stocks Set The Pace On Tuesday

    Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.

  • PR Newswire2 months ago

    BioPharmX to Participate in the 31st Annual ROTH Conference and the Oppenheimer 29th Annual Healthcare Conference

    SAN JOSE, Calif. , March 18, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced ...

  • PR Newswire2 months ago

    BioPharmX Reports Fourth Quarter and Full Year 2019 Financial Results

    SAN JOSE, Calif. , March 14, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports ...

  • Can We See Significant Institutional Ownership On The BioPharmX Corporation (NYSEMKT:BPMX) Share Register?
    Simply Wall St.2 months ago

    Can We See Significant Institutional Ownership On The BioPharmX Corporation (NYSEMKT:BPMX) Share Register?

    Every investor in BioPharmX Corporation (NYSEMKT:BPMX) should be aware of the most powerful shareholder groups. Insiders often own a large chunk of younger, smaller, companies while huge companies tend toRead More...

  • PR Newswire3 months ago

    BioPharmX Completes Enrollment in Phase 2b Trial of BPX-04 for Patients with Papulopustular Rosacea

    SAN JOSE, Calif., March 4, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced that it has completed enrollment of its Phase 2b clinical trial with BPX-041, a novel topical gel formulation of fully solubilized minocycline for the treatment of papulopustular rosacea. "This is an important milestone for our rosacea program and we look forward to reporting topline results from the study later this year," said David Tierney, BioPharmX CEO.

  • ACCESSWIRE3 months ago

    These Four Tech Stocks Could Test February Highs

    CORAL GABLES, FL / ACCESSWIRE / February 28, 2019 / The tech stock market has been a hotbed of excitement as a result of companies in the tech industry working to develop innovative new products to revamp the quality of life enjoyed by consumers. Consumers may not be aware of the fiscal happenings of companies working in tech, but they are likely more familiar with the products and services being released to the public. ParcelPal Technology Inc (PTNYF) (PKG), DPW Holdings Inc (NYSE American: DPW),BioPharmx Corporation (NYSE American: BPMX), and DropCar Inc (NASDAQ:DCAR) represent 4 tech stocks on the rise on Thursday.

  • PR Newswire3 months ago

    BioPharmX Receives Notice of Compliance Deadline Extension from NYSE American

    SAN JOSE, Calif., Feb. 27, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received a notice on February 25, 2019 from the NYSE American LLC (the "NYSE American") that granted the Company an extension from February 27, 2019 to April 30, 2019 to regain compliance with certain NYSE American continued listing standards related to the low price per share of the Company's common stock.

  • PR Newswire4 months ago

    BioPharmX Strengthens Board of Directors with Appointment of Industry Veteran Dr. R. Todd Plott

    SAN JOSE, Calif., Feb. 4, 2019 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today announced the appointment of veteran pharmaceutical developer R. Todd Plott, M.D., as an independent director. 16 years of which were spent  working as a research physician with the pharmaceutical industry.

  • GlobeNewswire4 months ago

    Report: Developing Opportunities within Match Group, Antero Resources, Boyd Gaming, Gorman-Rupp, Leap Therapeutics, and BioPharmX — Future Expectations, Projections Moving into 2019

    NEW YORK, Jan. 29, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • ACCESSWIRE4 months ago

    Market Rally Extends to Biotech

    HENDERSON, NV / ACCESSWIRE / January 9, 2019 / Markets are rallying in first full market week of 2019 and the biotech sector is responding as many oversold small caps are starting to rebound. We've found ...

  • PR Newswire5 months ago

    BioPharmX Receives Notice of Noncompliance from NYSE American

    MENLO PARK, Calif., Dec. 20, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, received a notice on December 17, 2018 from the NYSE American LLC (the "NYSE American") that the Company is not in compliance with the stockholders' equity requirements set forth in Section 1003(a)(i) and Section 1003(a)(ii) of the NYSE American Company Guide. The Company reported stockholders' equity of $0.6 million as of October 31, 2018 and net losses in its five most recent fiscal years ended January 31, 2018.  The continued listing standards require listed companies to maintain stockholders' equity of $2.0 million or more if they have reported losses from continuing operations and/or net losses in their three most recent fiscal years.  NYSE Regulation has reviewed the Company's compliance plan and has granted a plan period through September 24, 2019.

  • PR Newswire6 months ago

    BioPharmX Reports Third Quarter 2019 Financial Results

    MENLO PARK, Calif. , Dec. 6, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company focused on developing innovative medical dermatology products, today reports ...

  • Is BioPharmX Corporation’s (NYSEMKT:BPMX) Balance Sheet Strong Enough To Weather A Storm?
    Simply Wall St.6 months ago

    Is BioPharmX Corporation’s (NYSEMKT:BPMX) Balance Sheet Strong Enough To Weather A Storm?

    BioPharmX Corporation (NYSEMKT:BPMX), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is BPMX will Read More...

  • PR Newswire6 months ago

    BioPharmX Announces NYSE American Acceptance of Plan To Regain Listing Compliance

    MENLO PARK, Calif., Nov. 16, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX) (the "Company"), a specialty pharmaceutical company developing products for the dermatology market, announced that on November 1, 2018, NYSE Regulation accepted the Company's plan to regain compliance with the NYSE American LLC ("NYSE American") continued listing standards set forth in Sections 1003(a)(iii) of the NYSE American Company Guide. NYSE Regulation has reviewed the Company's compliance plan and has granted a plan period through September 24, 2019.

  • PR Newswire7 months ago

    BioPharmX Initiates Phase 2b Trial of BPX-04 for Rosacea

    MENLO PARK, Calif., Oct. 11, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced that it has enrolled the first subject in a Phase 2b clinical trial of BPX-04, a novel topical gel formulation of minocycline for the treatment of rosacea. The trial is a randomized, double-blind, vehicle-controlled study in subjects with inflammatory lesions of rosacea. The 12-week, multi-center study will evaluate BPX-04, a 1% topical minocycline, carried by the HyantX™ delivery system, a proprietary, anhydrous hydrophilic topical system developed by BioPharmX.  The trial plans to enroll 176 subjects at least 18 years old with an investigator's global assessment (IGA) score of 3 or 4 (moderate or severe), and 15 to 70 inflammatory lesions on their faces at baseline.

  • Who Are The Major Shareholders In BioPharmX Corporation (NYSEMKT:BPMX)?
    Simply Wall St.8 months ago

    Who Are The Major Shareholders In BioPharmX Corporation (NYSEMKT:BPMX)?

    The big shareholder groups in BioPharmX Corporation (NYSEMKT:BPMX) have power over the company. Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies.Read More...

  • PR Newswire8 months ago

    BioPharmX Corporation Announces David S. Tierney, M.D. Joined the Company as Chief Executive Officer

    MENLO PARK, Calif., Sept. 12, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today announced the appointment of David S. Tierney, M.D., as its chief executive officer.  Anja Krammer continues to serve in her roles as president and corporate secretary for BioPharmX. Dr. Tierney was also appointed as a director to the board of directors of BioPharmX. BioPharmX Corporation noted that Dr. Tierney is an accomplished healthcare executive with a proven record of achievements leading the growth of both pharmaceutical and medical device companies.

  • ACCESSWIRE8 months ago

    Today’s Research Reports on Stocks to Watch: Agile Therapeutics and BioPharmX

    NEW YORK, NY / ACCESSWIRE / September 12, 2018 / It was a day of unexplainable gains for two biotech stocks on Tuesday. Both Agile Therapeutics and BioPharmX catapulted higher despite any significant news. ...

  • PR Newswire9 months ago

    BioPharmX Reports Second Quarter 2019 Financial Results

    MENLO PARK, Calif. , Aug. 30, 2018 /PRNewswire/ -- BioPharmX Corporation (NYSE American: BPMX), a specialty pharmaceutical company developing products for the dermatology market, today reports financial ...